Tempus AI Director Nadja West Sells 3,000 Shares for $207,000
Key Points
The disposition involved 3,000 shares executed at $69.00 per share, totaling $207,000 in transaction value on August 28, 2026.
The shares traded were equal to 9.00% of the stake held before the filing, leaving the insider with a 0.0183% ownership interest.
The transaction was conducted directly by the insider and did not involve any indirect holding entities.
The sale was executed under a Rule 10b5-1 trading plan adopted on May 15, 2026, representing a scheduled liquidity event.
Nadja West, Director at Tempus AI, Inc. (NASDAQ:TEM), sold 3,000 shares of Class A Common Stock on Aug. 28, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $207,000 |
| Shares sold | 3,000 |
| Post-transaction shares (directly held) | 31,981 |
| Post-transaction value | $2.05 million |
Transaction value based on SEC Form 4 weighted average sale price ($69.00); post-transaction value based on Aug. 28, 2026, market close ($64.04).
Key questions
- What was the stated intent behind this transaction?
The sale was non-discretionary and executed pursuant to a Rule 10b5-1 trading plan established on May 15, 2026. These plans allow insiders to set up a pre-determined schedule for selling stock to avoid concerns regarding material non-public information. - How does this sale compare to the insider's remaining equity position?
The 3,000 shares sold represent 9.00% of Nadja West's direct equity stake before the transaction. Following the sale, the insider retains 31,981 shares of Class A Common Stock. - What has the equity's performance trend been leading up to this filing?
Shares of the healthcare technology company returned -13% over the one-period ending on the Aug. 28, 2026, the transaction date. The stock was priced at $63.05 as of the Aug. 31, 2026, market close.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-31) | $63.05 |
| Market Capitalization | $11.5 billion |
| Revenue (TTM) | $1.4 billion |
| Net Income (TTM) | -$254.4 million |
Company Snapshot
- Tempus AI operates a closed-loop healthcare technology platform that integrates clinician workflows with laboratory diagnostic capabilities, analytics, and multimodal data repositories, generating revenue through diagnostic testing services and platform licensing to healthcare providers.
- The company's business model centers on providing end-to-end next-generation sequencing (NGS) testing solutions and clinical applications through its Tempus platform and Hub product, enabling healthcare providers to deliver precision diagnostics while capturing value from data analytics.
- The company serves physicians, healthcare providers, and clinical laboratories seeking advanced diagnostic capabilities, with primary customers including hospital systems, oncology centers, and diagnostic laboratories across the United States.
Tempus AI is a healthcare technology company with a $11.5 billion market capitalization, generating $1.4 billion in TTM revenue through its integrated diagnostic and analytics platform.
The company operates at scale with 3,800 employees. It maintains a competitive position through its bi-directional clinical integration capabilities and proprietary multimodal data repository. However, it remains in an investment phase with TTM net losses of $254 million as it scales its platform adoption and expands its diagnostic service offerings.
What this transaction means for investors
This sale shouldn't concern investors. It was executed under a Rule 10b5-1 plan, which insiders commonly use to execute planned transactions without appearing to act on material non-public information.
Moreover, it represented a small percentage of the director's stake. Following the sale, the director still retains over 90% of the previous stake in the company's stock.
Importantly, Tempus AI continues to see rapid growth. TTM revenue surged 50% year over year. It's still primarily focused on scaling revenue, as it hasn't reported a profit yet. TTM operating loss was $283 million.
The stock trades at 8 times trailing revenue. That valuation implies more robust top-line growth and the expectation that Tempus AI will significantly improve its profitability as the business scales.
John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tempus AI. The Motley Fool has a disclosure policy.